The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1370
Abiraterone Acetate (Zytiga) for Metastatic Castration-Resistant Prostate Cancer
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved abiraterone acetate (Zytiga – Centocor Ortho Biotech) for oral treatment, in combination with prednisone, of metastatic castration-resistant prostate cancer in patients previously treated with docetaxel (Taxotere, and others). It is the first oral drug approved for this indication. Zytiga will compete with cabazitaxel (Jevtana) and sipuleucel-T (Provenge).1

MECHANISM OF ACTION — Abiraterone blocks biosynthesis of androgens by inhibiting CYP17, an enzyme required for androgen biosynthesis in the testicles, adrenal glands and prostate tumor. This mechanism is similar to that of ketoconazole, which has been used off-label for treatment of prostate cancer.

STANDARD TREATMENT — Medical or surgical castration, which stops androgen production by the testes, is the standard treatment for advanced ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Abiraterone Acetate (Zytiga) for Metastatic Castration-Resistant Prostate Cancer
Article code: 1370c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian